Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 28 от 154

Набира участници Фаза 3

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

Delayed Graft Function DGF Kidney Transplant

The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.

Начало: 19.05.2025 Край: 06.11.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +13 Alexion Pharmaceuticals, Inc. NCT06830798

Набира участници

A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo™ Aspiration System (STRIDE II)

Lower Extremity Acute Limb Ischemia LE ALI

The primary objective of this study is to collect and evaluate clinical evidence supporting the safety and performance of the Indigo™ Aspiration System in a patient population with lower extremity acute limb ischemia (LE ALI).

Начало: 18.05.2025 Край: 01.01.2029 Възраст: от 18 г.

Australia, Germany, Italy +2 Penumbra Inc. NCT06747117

Набира участници

Validity of ICU Clinician's Appraisal of Proportionality in CPR

Cardiac Arrest, Out-Of-Hospital

The VICAP-CPR study investigates whether doctors and nurses working in Intensive Care can determine neurological outcome and future quality of life after six months in patients treated for cardiac arrest outside the hospital based on clinical assessment in the first 24 hours after admission to Intensive Care. To conduct this study, the results of the questionnaire offered to Intensive Care doctors and nurses regarding the estimation of long-term neurological outcome and quality of life will be compared with the neurological outcome and quality of life as recorded in the STEPCARE study (NCT 05564754). The aim of the international STEPCARE study is to determine the best combination of post-resuscitation care to favourably influence survival and neurological outcome in patients treated for cardiac arrest outside hospital.

Начало: 18.05.2025 Край: 30.12.2026 Възраст: от 18 г.

Austria, Belgium, Finland +5 University Hospital, Ghent NCT07026773

Набира участници Фаза 3

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

Prostate Cancer Prostate Cancer Patients With Detectable PSA Following Prostatectomy Prostate Cancer Recurrent Prostate Cancer Patients Who Have Brachytherapy Seed Implant +2

The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer

Начало: 16.05.2025 Край: 31.12.2026 Възраст: от 18 г. Диагностика

Australia, United States Clarity Pharmaceuticals Ltd NCT06970847

Набира участници

Digital Mindset Intervention for Half Marathon Performance

Healthy Exercise Psychological Intervention

The goal of this randomized controlled trial is to test whether a brief digital mindset training program can improve performance among recreational runners training for a half marathon in New Zealand in 2025. The study will recruit healthy adult participants who are registered for an upcoming half-marathon event. The study aims to answer two main questions: 1. Does the mindset training program - designed to reframe common physical symptoms like fatigue or muscle soreness as signs of progress - help more runners complete the race and improve their official times, compared to standard training advice? 2. Does it support better training (e.g., longer peak training weeks) and faster physical recovery after the race? Researchers will compare participants who receive the mindset training program to those who receive widely followed half-marathon training content and a group who receive no study content, to see whether the mindset training leads to better half-marathon performance and training outcomes. Participants will: * Complete a brief online survey at the start of the study * Receive and engage with four pieces of digital content across nine weeks before the half-marathon race (if assigned to a training group) * Complete a follow-up survey after the half-marathon

Начало: 15.05.2025 Край: 01.09.2025 Възраст: от 18 г. Поддържаща грижа

New Zealand University of Auckland, New Zealand NCT06972121

Набира участници Фаза 1

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

Head and Neck Squamous Cell Carcinoma

This study is open to adults with head and neck cancer. The purpose of this study is to find out whether combining different study medicines makes tumors shrink in people with head and neck cancer. The tested medicines in this study are antibodies that act in different ways against cancer. BI 770371 and pembrolizumab may help the immune system fight cancer. Cetuximab blocks growth signals and may prevent the tumor from growing. Participants are put into 3 groups randomly. Each group receives a different combination of study medicines. All study medicines are given as an infusion into a vein at the study site. Participants can stay in the study as long as they benefit from treatment. Doctors regularly check the size of the tumor and check whether it has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects.

Начало: 14.05.2025 Край: 31.07.2027 Възраст: от 18 г. Лечение

Australia, Brazil, Bulgaria +19 Boehringer Ingelheim NCT06806852

Набира участници

A Study of Transcatheter Aortic Valve Replacement Case Selection and Valve Sizing Using the ABC Bicuspid Sizing Algorithm

Aortic Stenosis

The goal of this study is to learn what effects the ABC Bicuspid Sizing Algorithm has on the clinical outcomes of patients with bicuspid aortic stenosis after having a transcatheter aortic valve replacement (TAVR) using the Sapien 3 valve. The main questions the study aims to answer are: 1. Does the ABC Bicuspid Sizing Algorithm increase the technical success at exit from the procedure room? 2. Does the ABC Bicuspid Sizing Algorithm increase the device success at 30 days after the procedure? Participants already being evaluated for a TAVR as part of their regular medical care for bicuspid aortic stenosis will have their diagnostic images assessed using the ABC Bicuspid Sizing Algorithm to help determine their procedure type and valve size. They will have visits 30 days and one year after their procedure.

Начало: 13.05.2025 Край: 01.12.2027

Australia, Canada, Colombia +4 World Health Research Inc. NCT06991517

Набира участници Фаза 2

A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia.

Insomnia

The goal of this clinical trial is to explore the potential neuroprotective benefits of a dual orexin receptor antagonist (DORA) in adults with insomnia. The main questions it aims to answer are: * Does the DORA reduce blood-based phosphorylated TAU181, in adults with insomnia, when compared to placebo * Does the DORA reduce other blood-based biomarkers of neurodegeneration, including phosphorylated TAU217, amyloid beta 40:42 ratio, Neurofilament Light Chain (NFL) and Glial Fibrillary Acidic Protein (GFAP), when compared to placebo. Participants will: * Take 10mg Lemborexant nightly for two weeks * Take a matching placebo nightly for two weeks * Visit the research institute for a screening visit and for an overnight visit at the conclusion of each study drug treatment (3 visits in total).

Начало: 13.05.2025 Край: 01.04.2026 Възраст: 40–65 г. Друго

Australia Woolcock Institute of Medical Research NCT06823752

Набира участници Фаза 1/2

Pomalidomide as an Immune-enhancing Agent for the Control of HIV

HIV-1 Infection

This study is designed to evaluate the safety and efficacy of pomalidomide in HIV-1-infected individuals on ART and to determine the impact of pomalidomide on virological control in people living with HIV during an analytical treatment interruption.

Начало: 13.05.2025 Край: 31.03.2026 Възраст: 18–70 г. Лечение

Australia, Denmark University of Aarhus NCT06660498

Набира участници Фаза 1

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

Non Small Cell Lung Cancer

This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations.

Начало: 13.05.2025 Край: 01.12.2028 Възраст: от 18 г. Лечение

Australia, United States Dizal Pharmaceuticals NCT06905197

Набира участници

Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

Age-Related Macular Degeneration

1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.

Начало: 12.05.2025 Край: 01.11.2026 Възраст: от 50 г.

Argentina, Australia, France +4 University of Wisconsin, Madison NCT06924021

Набира участници

Comparison of Dietetics Support With and Without Continuous Glucose Monitoring in Individuals With Type 2 Diabetes.

Type 2 Diabetes Mellitus (T2DM) Continuous Glucose Measurement Dietary Modification

A parallel, single-blinded, randomised clinical trial conducted remotely across Australia from the Mary MacKillop Institute for Health Research (MMIHR, Australian Catholic University) for individuals with type 2 diabetes, by researchers from Australian Catholic University, University of Adelaide, University of Queensland, University of Wollongong, Monash University, Monash Partners, Deakin University, La Trobe University and Melbourne University.

Начало: 12.05.2025 Край: 28.11.2026 Възраст: от 18 г. Лечение

Australia Australian Catholic University NCT06888687

Набира участници Фаза 3

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Amyloidosis Amyloid Cardiomyopathy Transthyretin Amyloidosis Cardiomyopathies +2

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR (ATTRwt). The other way occurs when a person inherits a defective TTR gene that causes the TTR protein to spontaneously fall apart. This form of the disease is known as variant ATTR (ATTRv) and can be detected in adults by a genetic test of their TTR gene before they age. Amyloid build-up in the heart causes the heart wall to become thick and stiff and can result in heart failure and even death. Accumulation of TTR amyloid in the heart is known as transthyretin amyloid cardiomyopathy or ATTR-CM. Amyloid can also deposit in the nerve tissues leading to nerve problems. Accumulation of TTR in the nerves is known as transthyretin amyloid polyneuropathy or ATTR-PN. Acoramidis is an experimental drug designed to bind tightly to TTR in the blood and stabilize its structure, so it does not form the harmful amyloid plaques that can cause damage to organs. This study is intended to determine if treatment with acoramidis in participants with ATTRv who have not yet developed any symptoms of disease can prevent or delay the development of ATTR-CM or ATTR-PN disease. If adults with an inherited defective TTR gene are treated early before any of the symptoms of disease have developed, it may be possible to delay the onset or prevent the disease entirely.

Начало: 12.05.2025 Край: 01.12.2032 Възраст: 18–75 г. Превенция

Argentina, Australia, Belgium +19 Eidos Therapeutics, a BridgeBio company NCT06563895

Набира участници Фаза 3

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Moderately to Severely Active Crohns Disease

This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).

Начало: 12.05.2025 Край: 30.04.2033 Възраст: 16–80 г. Лечение

Argentina, Australia, Belgium +20 Hoffmann-La Roche NCT06819891

Набира участници Фаза 1/2

A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus

Obesity Diabetes Mellitus, Type 2

This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple doses of ARO-ALK7 in adult participants with obesity without Type 2 Diabetes Mellitus (T2DM) (Part 1), and the safety, tolerability and PD of multiple doses of ARO-ALK7 in adult participants with obesity with and without T2DM, either as monotherapy or in combination with tirzepatide (Part 2).

Начало: 09.05.2025 Край: 01.10.2026 Възраст: 18–65 г. Лечение

Australia, New Zealand Arrowhead Pharmaceuticals NCT06937203

Набира участници Фаза 1

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

Prostate Cancer

A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy

Начало: 08.05.2025 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia, United States SURGE Therapeutics NCT06450106

Набира участници Фаза 1

A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

This study is a randomized, blinded, placebo-controlled single (SAD) and multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and exploratory clinical activity of BBT002 in healthy volunteers (HVs) and in adult patients with Chronic Obstructive Pulmonary Disease (COPD).

Начало: 08.05.2025 Край: 31.03.2027 Възраст: 18–75 г. Лечение

Australia Bambusa Therapeutics NCT06944925

Набира участници

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

Age-Related Macular Degeneration Age-related Macular Degeneration (ARMD) Intermediate AMD Geographic Atrophy Secondary to Age-related Macular Degeneration

The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD. Participants will: * Undergo an initial loading regimen, followed by 7 maintenance over the course of 11 months. * Participants will return monthly through Month 14 (3 months post-last treatment) for evaluation and monitoring.

Начало: 07.05.2025 Край: 31.12.2029 Възраст: от 60 г. Лечение

Australia, New Zealand, United Kingdom +1 i-Lumen Scientific AUS PTY LTD NCT06662162

Набира участници Фаза 2/3

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)

Myeloma Non Hodgkin's Lymphoma Leukemia

This study is being conducted to find out how safe and effective different strategies of infection prevention are in comparison to each other, for preventing infection in patients with blood cancers. The best way to find out this information is to directly compare the effect of different treatment strategies in patients with blood cancers. We want to know how these different treatments impact on your health and your use of healthcare services. This research project uses an Adaptive Platform Design. This design allows the researchers to compare multiple infection prevention strategies within the same trial at the same time (rather than running separate trials), to analyse results as the trial occurs and to add new research questions during the course of the trial. The treatments that you may receive as part of the study will be determined by which domain(s) of the platform you participate in. By combining data collected within each domain as part of the platform, the researchers can investigate and compare treatment strategies and infection outcomes across a broader range of participants.

Начало: 07.05.2025 Край: 31.03.2027 Възраст: от 18 г. Лечение

Australia Monash University NCT07202078

Набира участници Фаза 2/3

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

Myeloma Non-Hodgkin's Lymphoma Leukemia

This is an adaptive platform study to find out how safe and effective different strategies are in comparison to each other, for preventing infection in patients with blood cancers. It is a comparison between Immunoglobulin and antibiotics use.

Начало: 06.05.2025 Край: 31.03.2027 Възраст: от 18 г. Лечение

Australia Monash University NCT07202052

1 … 26 27 28 29 30 … 154